TY - JOUR
T1 - Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease
T2 - report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.
AU - Silverberg, Mark S.
AU - Satsangi, Jack
AU - Ahmad, Tariq
AU - Arnott, Ian D.R.
AU - Bernstein, Charles N.
AU - Brant, Steven R.
AU - Caprilli, Renzo
AU - Colombel, Jean Frédéric
AU - Gasche, Christoph
AU - Geboes, Karel
AU - Jewell, Derek P.
AU - Karban, Amir
AU - Loftus, Edward V.
AU - Peña, A. Salvador
AU - Riddell, Robert H.
AU - Sachar, David B.
AU - Schreiber, Stefan
AU - Steinhart, A. Hillary
AU - Targan, Stephan R.
AU - Vermeire, Severine
AU - Warren, B. F.
PY - 2005/9
Y1 - 2005/9
N2 - The discovery of a series of genetic and serological markers associated with disease susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an integrated classification system involving clinical, serological and genetic parameters. The Working Party has reviewed current clinical classification systems in Crohn's disease, ulcerative colitis and indeterminate colitis, and provided recommendations for clinical classification in practice. Progress with respect to integrating serological and genetic markers has been examined in detail, and the implications are discussed. While an integrated system is not proposed for clinical use at present, the introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
AB - The discovery of a series of genetic and serological markers associated with disease susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an integrated classification system involving clinical, serological and genetic parameters. The Working Party has reviewed current clinical classification systems in Crohn's disease, ulcerative colitis and indeterminate colitis, and provided recommendations for clinical classification in practice. Progress with respect to integrating serological and genetic markers has been examined in detail, and the implications are discussed. While an integrated system is not proposed for clinical use at present, the introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
UR - http://www.scopus.com/inward/record.url?scp=84894353884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894353884&partnerID=8YFLogxK
M3 - Article
C2 - 16151544
AN - SCOPUS:84894353884
VL - 19 Suppl A
SP - 5A-36A
JO - Canadian Journal of Gastroenterology and Hepatology
JF - Canadian Journal of Gastroenterology and Hepatology
SN - 2291-2789
ER -